Richard Shelton is a Treatment of Major Depression physician affiliated with University of Alabama at Birmingham Hospital. OpenAlex indexes 343 publications with 20,564 citations (h-index 68); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Psychiatry profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Richard Shelton is affiliated with University of Alabama at Birmingham Hospital. The public record shows 343 publications with 20,564 citations (h-index 68), centered on Treatment of Major Depression, Bipolar Disorder and Treatment, Tryptophan and brain disorders. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 11 companies, 6 NIH-funded awards (2012–2025).
- Most recent indexed publication: 2024 · Molecular psychiatry
- Top research focus: Treatment of Major Depression
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 206.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
Sponsor: University of Alabama at Birmingham
- MicroRNA Correlates of Childhood Maltreatment and Suicidality
Sponsor: University of Alabama at Birmingham
Industry payments
Updated 14 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20252 payments
- Janssen Scientific Affairs, LLCProgram year20252 payments
- Axsome Therapeutics, Inc.Program year20251 payment
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Aminoketone100%Bupropion Xl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
6 NIH research awards on record, funded 2012–2025 per NIH RePORTER. The latest:
- Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
University of Alabama at Birmingham
FY2025$1,479,918RF1MH130539 - MicroRNA Correlates of Childhood Maltreatment and Suicidality
University of Alabama at Birmingham
FY2025$702,491R01MH124248 - Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
University of Alabama at Birmingham
FY2024$739,959R01MH130539
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited works
by citation count (OpenAlex)- 01Antidepressant Drug Effects and Depression SeverityArticle2,016 citations2010
- 02Cognitive Therapy vs Medications in the Treatment of Moderate to Severe DepressionArticle995 citations2005
- 03
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/richard-shelton-md-24fca4a4
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Richard-Shelton-3
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature themWe list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Marc Passman
University of Alabama at Birmingham Hospital
Rebecca Arend, MD
University of Alabama at Birmingham Hospital
Angelo Gaffo-Llontop
University of Alabama at Birmingham Hospital
Matthew Stoll, MD, PhD
University of Alabama at Birmingham Hospital
Charles Nemeroff, MD
Dell Medical School
Maurizio Fava, MD
Massachusetts General Hospital
John Krystal, MD
Yale University
Jeffrey Lieberman, MD
Columbia University College of Physicians and Surgeons